索拉非尼联合顺铂抑制卵巢癌H08910细胞生长的体外研究  

The in vitro study on sorafenib combined with cisplatin for ovarian cancer cell H08910 growth inhibition

作　　者：胡丁月[1] 张爽[1] 

机构地区：[1]辽宁医学院附属第一医院妇科,辽宁锦州121000

出　　处：《中国医学工程》2012年第12期28-29,共2页China Medical Engineering

摘　　要：目的对索拉非尼联合顺铂抑制卵巢癌H08910细胞生长进行体外研究。方法探讨索拉非尼、顺铂单用以及索拉非尼与顺铂联合应用对卵巢癌H08910细胞增殖的抑制率、细胞凋亡率、细胞周期影响。检测细胞增殖的抑制率采用四甲基偶氮唑蓝方法,检测细胞凋亡率、细胞周期应用流式细胞仪。结果联合用药组对卵巢癌H0-8910细胞增殖抑制率明显高于单独用药组,两者能够诱导细胞凋亡及阻滞细胞周期,在联合应用时表现出协同作用趋势。结论索拉非尼能够将患者对化疗药物的敏感性提高,降低化疗药物应用剂量及毒副作用,可能成为化疗药物良好辅助用药。【Objective】To make an in vitro study on sorafenib combined with cisplatin for ovarian cancer cell H08910 growth inhibition.【Methods】 We studied on the effect of inhibition rate of ovarian cancer cell H08910 proliferation,the rate of apoptosis and cell cycle when used sorafenib or cisplatin alone,and Sorafenib combined with cisplatin.We used tetramethyl azo blue method to detect the inhibition rate of cell proliferation and flow cytometry to detect the rates of apoptosis and cell cycle.【Resluts】 The combined treatment group was significantly higher than simplex treatment group on inhibition rate of ovarian cancer cell H08910 proliferation.They can induce apoptosis and block the cell cycle in both groups.It demonstrated the synergies trend in combined group.【Conclusion】 Sorafenib can increase the sensitivity to chemotherapy drugs of patients and reduce the dose of chemotherapy drugs and side effects.It may become a good assistant drug for chemotherapy.

关 键 词：索拉非尼 顺铂 卵巢癌H08910细胞 体外研究 

分 类 号：R737.31[医药卫生—肿瘤]